Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$23.88 USD
+0.09 (0.38%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $23.86 -0.02 (-0.08%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Arcturus Therapeutics (ARCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$65.86 | $140.00 | $18.00 | 176.84% |
Price Target
Based on short-term price targets offered by seven analysts, the average price target for Arcturus Therapeutics comes to $65.86. The forecasts range from a low of $18.00 to a high of $140.00. The average price target represents an increase of 176.84% from the last closing price of $23.79.
Analyst Price Targets (7 )
Broker Rating
Arcturus Therapeutics currently has an average brokerage recommendation (ABR) of 1.44 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by nine brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the nine recommendations deriving the current ABR, eight are Strong Buy, representing 88.89% of all recommendations. A month ago, Strong Buy represented 88.89%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/ARCT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.44 | 1.44 | 1.44 | 1.44 | 1.44 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/2/2024 | H.C. Wainwright & Co. | Ed Arce | Strong Buy | Strong Buy |
5/9/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
5/8/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
3/11/2024 | Canaccord Genuity | Whitney Ijem | Strong Buy | Strong Buy |
3/8/2024 | William Blair | Myles R Minter | Strong Buy | Strong Buy |
3/8/2024 | Wells Fargo Securities | Yanan Zhu | Strong Buy | Strong Buy |
3/1/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Strong Buy |
2/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
10/25/2023 | Robert W. Baird & Co. | Joel L Beatty | Strong Sell | Strong Sell |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.44 |
ABR (Last week) | 1.44 |
# of Recs in ABR | 9 |
Average Target Price | $65.86 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -1.50 |